Direct-to-Employer GLP-1 Models: An Employer's Guide to DTE Programs

Dr. Nishu Uppal

Dr. Nishu Uppal

Medical Director

Dr. Uppal is a practicing internal medicine physician and healthcare policy researcher trained at Brigham and Women's Hospital. He has published in leading journals including NEJM, JAMA, and Health Affairs, and holds an MD from Harvard Medical School and an MBA from Harvard Business School.

Benefits leaders face an impossible equation. Employee demand for GLP-1 medications like Wegovy® and Zepbound® keeps climbing, 54% of employees say they would consider them if covered, but traditional PBM coverage makes costs opaque, unpredictable, and difficult to control. Direct-to-Employer (DTE) GLP-1 programs have emerged as the response: a transparent, clinically-supervised alternative to the PBM pathway that gives employers direct pricing from manufacturers and a clearer line of sight into spend.

This guide explains how DTE GLP-1 models work, how they differ from PBM coverage, what they cost, and what to look for when evaluating a program for your workforce.

What Is a Direct-to-Employer GLP-1 Program?

A Direct-to-Employer (DTE) GLP-1 program is a benefit arrangement in which employers contract directly with a vendor, bypassing the PBM, to offer GLP-1 medications at manufacturer-negotiated rates. The employer sets the cost share, sees transparent per-dose pricing, and typically receives wraparound clinical care alongside the medication.

Instead of adding GLP-1s to a standard pharmacy benefit managed through rebate-driven PBM contracts, the employer carves the medication out into a dedicated program with predetermined pricing. Most DTE programs are built through partnerships between drug manufacturers (Eli Lilly, Novo Nordisk), third-party administrators, and clinical care vendors. Goodpath's version of this model is called Goodpath WeightRx Total Support: employer-subsidized, rebate-free, and embedded inside a whole-person integrative care program.

The services bundled into DTE programs vary widely. Some offer pharmacy fulfillment only. Others, including Goodpath, pair the medication with a dedicated Health Coach, a multidisciplinary clinical team, and treatment for the comorbidities that drive long-term weight outcomes.

How DTE GLP-1 Models Differ from Traditional PBM Coverage

The core difference is transparency. PBM coverage hides the true net cost of GLP-1s behind rebate contracts and year-end reconciliation, while DTE programs expose the per-dose price up front and give employers real-time visibility into spend.

Under a traditional PBM arrangement, employers rely on the PBM to negotiate drug pricing, set formulary decisions, and process pharmacy claims. That structure introduces pricing opacity: employers often do not know the true net cost of covering Wegovy® or Zepbound® until rebates settle months after the fact. With DTE:

  • Pricing is set in advance. The employer sees the exact per-dose cost before enrolling members.
  • Utilization data is visible in-year. Employers can forecast pharmacy spend as it accrues rather than waiting for year-end reporting.
  • Rebates are removed from the equation. The price is the price. No hidden fees, no rebate float.
  • Cost share is employer-controlled. The employer decides how much, if any, the Member pays.

For employers who have been burned by GLP-1 cost volatility, this shift from retrospective to prospective pricing is often the decision point.

How DTE Pricing Compares to PBM GLP-1 Costs

DTE GLP-1 programs typically deliver 35% or more in savings compared to PBM pricing on medications like Wegovy® and Zepbound®. Pricing is tied to direct manufacturer partnerships, so employers capture the savings immediately rather than waiting for rebates to trickle through the PBM.

Covering GLP-1s in any form will increase pharmacy spend given the demand. That is unavoidable. The question is not whether GLP-1 coverage raises costs but whether the employer can make that spend predictable, contained, and clinically effective. DTE pricing does three things to support cost containment:

  • Lower unit cost. Direct manufacturer pricing meaningfully undercuts PBM list prices for the same medication.
  • Predictable monthly spend. Fixed per-dose pricing lets finance teams budget with confidence.
  • Responsiveness to price changes. When a manufacturer adjusts pricing, employers capture the benefit immediately, not after a year of PBM reconciliation.

Key Features of DTE GLP-1 Programs

Every credible DTE GLP-1 program should deliver six things. When evaluating vendors, use this as your checklist.

  1. Transparent, predictable pricing. Upfront per-dose pricing with no rebate structures and no hidden fees. Employers should see the exact cost before signing.
  2. Flexible benefit design. Employers should be able to customize cost share and program scope to fit their workforce and budget.
  3. Controlled distribution. Prescriptions route through designated partner pharmacies or mail-order fulfillment, ensuring reliable inventory and timely delivery.
  4. Integrative clinical support. Medication alone does not produce sustained outcomes. Strong DTE programs bundle GLP-1 access with whole-person care: nutrition, behavioral health, sleep, movement, and treatment for the comorbidities that typically travel with obesity. At Goodpath, that means a dedicated Health Coach and a clinical team spanning 20+ medical specialties, with personalized support for side effect management, adherence, and long-term maintenance.
  5. Evidence-based eligibility and clinical guardrails. The program should use FDA-backed clinical criteria to determine who qualifies and monitor treatment duration to ensure Members stay on therapy long enough to achieve durable outcomes. Early discontinuation produces sunk costs with minimal clinical benefit.
  6. Seamless Member experience. Telehealth consults, digital progress tracking, simple payment, and shipping. The interface should feel frictionless because engagement is what drives outcomes.

The first five features control cost, and the sixth drives engagement. Programs that only deliver one or two of these are not DTE programs in any meaningful sense; they are pharmacy discount cards with extra paperwork.

Why Clinical Support Is the Real Differentiator

GLP-1s are powerful accelerators, but they are not complete or lasting solutions on their own. Without behavioral support and comorbidity treatment, adherence drops, side effects derail progress, and weight often returns after discontinuation. Employers who buy medication without clinical wraparound are paying for drugs that do not produce the health or cost outcomes they were promised.

84% of individuals with obesity have at least one comorbid condition, including chronic pain, sleep dysfunction, depression, and metabolic disease. Those comorbidities are not side effects of weight; they are often the reason weight has been so hard to treat. A GLP-1 program that ignores them leaves durable outcomes on the table.

This is why DTE programs with integrative clinical care outperform pharmacy-only programs on every metric that matters:

  • 77% of Goodpath Members achieve sustained weight loss
  • 74% improve in two or more conditions simultaneously
  • 30-51% reduction in short-term disability incidence
  • $2,292 PMPY reduction in total cost of care, independently validated by an actuarial firm

The medication is a powerful tool, and the clinical program is what makes the medication work.

Benefits and Considerations for Employers

The advantages of DTE GLP-1 programs include transparent pricing, integrative clinical support, in-year utilization data, and appropriate clinical guardrails that reduce waste and improve adherence. Strong programs also reduce downstream medical costs by managing nutrition, mental health, sleep, and side effects in real time, avoiding ER visits, medication waste, and early drop-off.

A few considerations to think through before moving forward:

  • DTE programs coexist with the PBM. Switching GLP-1s to a DTE model does not affect coverage for other medications. All other prescriptions continue through the PBM.
  • Expect a carve-out process. There is an operational lift to stand the program up alongside existing pharmacy benefits. In most cases, the carve-out is as simple as a plan administration change, but consultants should walk employers through the steps.

Bottom Line: What DTE Means for Employers

The GLP-1 question for employers has moved past yes-or-no. It is now: how do we cover these medications in a way that is cost-sustainable, clinically effective, and transparent to us and our employees? DTE GLP-1 programs are the most credible answer on the market for employers who want real cost control and real clinical outcomes.

The catch is that not all DTE programs are created equal. Pharmacy-only DTE programs deliver pricing transparency but leave outcomes to chance. Integrative DTE programs, built on a whole-person clinical foundation, deliver both the cost control and the durable health improvements that justify the investment.

Goodpath's WeightRx Program combines direct-to-employer pricing with a multi-disciplinary clinical care model that treats weight alongside the comorbidities that drive long-term spend. For employers evaluating DTE, that combination is the difference between paying for medication and paying for outcomes.

Ready to see what WeightRx could look like for your workforce? Let our team know.

Frequently Asked Questions About DTE GLP-1 Programs

What is a Direct-to-Employer GLP-1 program?

A Direct-to-Employer (DTE) GLP-1 program is a benefit arrangement where employers contract directly with a vendor, bypassing the PBM, to provide GLP-1 medications at transparent manufacturer-negotiated rates. Employers set the cost share and typically receive wraparound clinical care alongside the medication. For example, Goodpath's WeightRx program is a DTE offering through Eli Lilly's Employer Connect and Novo Nordisk's programs.

How much do employers save with DTE GLP-1 programs compared to PBM coverage?

DTE GLP-1 programs typically save employers 35% or more compared to traditional PBM pricing on medications like Wegovy® and Zepbound®. Savings come from direct manufacturer pricing, the elimination of rebate-driven contracts, and transparent per-dose costs that employers can budget against.

Do DTE GLP-1 programs replace the PBM?

No. DTE GLP-1 programs are carve-outs that run alongside the existing PBM arrangement. All other medications continue to be covered through the PBM. Only the GLP-1 benefit is moved into the DTE program.

What is WeightRx Total Support?

WeightRx Total Support is Goodpath's Direct-to-Employer GLP-1 program. It combines manufacturer-negotiated pricing for Wegovy® and Zepbound® with a whole-person integrative care model, including a dedicated Health Coach, clinical oversight, and comorbidity treatment. Pricing is employer-set, rebate-free, and 35%+ below PBM rates.

How complicated is it to carve out GLP-1 coverage from the PBM?

The carve-out process is simpler than it sounds. In most plan setups, it is a plan administration change that can be completed in weeks, not months. Consultants and the DTE vendor handle most of the operational work, and the upside is direct pricing, transparent cost structure, and clinical oversight that PBMs do not provide.

Which employers are a good fit for DTE GLP-1 programs?

DTE GLP-1 programs generally work best for self-insured employers with 200 or more benefits-eligible lives, because the economics of direct pricing compound with scale. Employers in industries with high comorbidity burden, such as manufacturing, healthcare systems, and logistics, typically see the strongest clinical and financial returns.

What should employers look for when evaluating a DTE GLP-1 vendor?

Look for six features: transparent per-dose pricing, flexible benefit design, reliable distribution, integrative clinical care alongside the medication, evidence-based eligibility and clinical guardrails, and a seamless member experience. Pharmacy-only DTE programs deliver pricing but leave clinical outcomes to chance; integrative programs deliver both.